Neurodevelopmental Disorders, Schizophrenia Spectrum Disorders and Catatonia: The “Iron Triangle” Rediscovered in a Case Report
Pamela Fantozzi,
Claudia Del Grande,
Stefano Berloffa,
Greta Tolomei,
Carmen Salluce,
Antonio Narzisi,
Gianluca Salarpi,
Barbara Capovani,
Gabriele Masi
Affiliations
Pamela Fantozzi
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Calambrone, 56018 Pisa, Italy
Claudia Del Grande
Azienda Usl Toscana Nord-Ovest, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “Santa Chiara”, 38122 Pisa, Italy
Stefano Berloffa
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Calambrone, 56018 Pisa, Italy
Greta Tolomei
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Calambrone, 56018 Pisa, Italy
Carmen Salluce
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Calambrone, 56018 Pisa, Italy
Antonio Narzisi
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Calambrone, 56018 Pisa, Italy
Gianluca Salarpi
Azienda Usl Toscana Nord-Ovest, Department of Mental Health, Pontedera, 38122 Pisa, Italy
Barbara Capovani
Azienda Usl Toscana Nord-Ovest, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “Santa Chiara”, 38122 Pisa, Italy
Gabriele Masi
IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Calambrone, 56018 Pisa, Italy
Catatonia is a complex neuropsychiatric syndrome, occurring in the context of different psychiatric and neurodevelopmental disorders, in neurological and medical disorders, and after substance abuse or withdrawal. The relationship between Autism Spectrum Disorder (ASD), Schizophrenia Spectrum Disorders (SSDs) and catatonia has been previously discussed, with the three disorders interpreted as different manifestations of the same underlying brain disorder (the “Iron Triangle”). We discuss in this paper the diagnostic, clinical and therapeutic implications of this complex relationship in an adolescent with ASD, who presented an acute psychotic onset with catatonia, associated with mixed mood symptoms. Second-generation antipsychotics were used to manage psychotic, behavioral and affective symptoms, with worsening of the catatonic symptoms. In this clinical condition, antipsychotics may be useful at the lowest dosages, with increases only in the acute phases, especially when benzodiazepines are ineffective. Mood stabilizers with higher GABAergic effects (such as Valproate and Gabapentin) and Lithium salts may be more useful and well tolerated, given the frequent association of depressive and manic symptoms with mixed features.